It is of note that the first biopsy exhibited markers that are associated with a clinical benefit to immunotherapies, including mismatch repair deficiency, high mutation burden and high predicted CD8+ T cell scores [5,20,21]. This evidence concerns the gene CD8A and mismatch repair cancer syndrome 1.